William Shakespeare - 06 Oct 2021 Form 3 Insider Report for Theseus Pharmaceuticals, Inc.

Role
President of Research and Development
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
06 Oct 2021
Net transactions value
$0
Form type
3
Filing time
06 Oct 2021, 19:01:06 UTC
Next filing
14 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding THRX Common Stock 388,324 06 Oct 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding THRX Stock Option (right to buy) 06 Oct 2021 Common Stock 344,344 $0.3175 Direct F1
holding THRX Stock Option (right to buy) 06 Oct 2021 Common Stock 36,066 $4.03 Direct F2
holding THRX Stock Option (right to buy) 06 Oct 2021 Common Stock 227,607 $4.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are immediately exercisable in full due to early exercise rights, subject to the issuer's right of repurchase. The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 18, 2020, subject to the Reporting Person's continuous service with the issuer.
F2 The options are immediately exercisable in full due to early exercise rights, subject to the issuer's right of repurchase. The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 18, 2020, subject to the Reporting Person's continuous service with the issuer.
F3 The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after May 27, 2021, subject to the Reporting Person's continuous service with the issuer.

Remarks:

President of Research and Development